ASNS - Arsanis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.03
-0.14 (-4.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.17
Open3.20
Bid3.05 x 1700
Ask3.48 x 1400
Day's Range2.98 - 3.29
52 Week Range2.94 - 28.69
Volume204,827
Avg. Volume93,544
Market Cap43.312M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-7.11
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
Trade prices are not sourced from all markets
  • Arsanis Enters Oversold Territory
    Zacks6 days ago

    Arsanis Enters Oversold Territory

    Arsanis Enters Oversold Territory

  • Business Wire24 days ago

    INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether Arsanis, Inc. (“Arsanis” or the “Company”) (ASNS) complied with the federal securities laws. On June 28, 2018, Arsanis announced the discontinuation of its Phase 2 clinical trial of ASN100, a preventive drug for mechanically ventilated patients with a high risk of contracting pneumonia. Arsanis disclosed that an analysis completed by an independent drug review committee found that continuing the trial was “futile” because the target primary end-point likely would not be met upon completion. If you purchased Arsanis common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq.

  • GlobeNewswire24 days ago

    Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100

    Arsanis, Inc. (ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC). Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion and recommended that trial enrollment be discontinued.

  • GlobeNewswirelast month

    Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program

    Arsanis, Inc. (ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB200, LLC, a portfolio company of Bravos Biosciences, LLC, has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected monoclonal antibodies (mAbs) targeting K. pneumoniae that were discovered by Arsanis in its ASN300 program, including lead preclinical development candidate, ASN-5. In April 2018, Arsanis entered into a similar agreement for its ASN200 program, targeting E. coli, with Bravos Biosciences subsidiary BB100, LLC.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property Partners, Arsanis, QIWI, and Stitch Fix — Discovering Underlying Factors of Influence

    NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford ...

  • Business Wire2 months ago

    Arsanis Reports Business Highlights and Financial Results for First Quarter 2018

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018.

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • Business Wire3 months ago

    Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that the company will present five scientific posters at the 28th European Congress of Clinical Microbiology and Infectious Diseases in Madrid, Spain from April 21 – 24, 2018. The posters will highlight new research findings and supportive ...

  • Business Wire4 months ago

    Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB100, LLC has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to monoclonal antibodies targeting ...

  • Business Wire4 months ago

    Arsanis to Present at the Needham & Company 17th Annual Healthcare Conference

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that CEO René Russo, PharmD, BCPS, will present a company overview at the Needham & Company 17th Annual Healthcare Conference on March 27, 2018, at 12:45 p.m.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these sizzling biotech stocks keep the momentum going?

  • Business Wire4 months ago

    Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the United States Patent and Trademark Office issued U.S.

  • Business Wire4 months ago

    Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2017.

  • Business Wire5 months ago

    Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that CEO René Russo, PharmD, BCPS, will present a company overview at the 38th Annual Cowen and Company Health Care Conference on March 12, 2018, at 12:00 p.m.

  • What You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROE
    Simply Wall St.7 months ago

    What You Must Know About Arsanis Inc’s (NASDAQ:ASNS) ROE

    With an ROE of 218.55%, Arsanis Inc (NASDAQ:ASNS) outpaced its own industry which delivered a less exciting 16.06% over the past year. On the surface, this looks fantastic since weRead More...

  • Business Wire8 months ago

    Arsanis Announces Closing of Initial Public Offering

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10.00 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters ...